Navigation Links
Accelerate Diagnostics Announces Final Results of Rights Offering
Date:8/13/2013

TUCSON, Ariz., Aug. 13, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), announced today that it has completed its previously announced rights offering. Through broad participation from both insiders and non-insider investors, the Company raised $20,000,000, including proceeds from a standby commitment made by Abeja Ventures, LLC.

Stockholders subscribed for a total of 1,871,410 shares of the Company's common stock pursuant to their basic subscription privileges, representing a 75% participation rate.  In addition, stockholders over subscribed for a total of 1,077,471 shares of which 203,062 shares were issued following exclusions based on the outcome of the basic subscription.  Finally, a total of 413,090 shares of common stock will be issued to the standby purchaser.  In the aggregate, the Company will issue 2,487,562 shares of common stock of which 1,719,425 shares, or 69%, were acquired by directors of the company.

"The broad participation of our directors and general shareholder base in this offering underscores the great ongoing support for the company, our technology, and its market potential," said Lawrence Mehren, CEO of Accelerate Diagnostics, Inc.  

The shares of the Company's common stock issuable pursuant to the rights offering and Standby Purchase Agreement will be issued to stockholders and the standby purchaser as promptly as practicable.

The rights offering was made pursuant to a Registration Statement on Form S-3 that was filed with the Securities and Exchange Commission (SEC) and became effective on July 12, 2013.  The rights offering was made solely by means of the prospectus that was filed with the SEC on July 12, 2013. For questions about the rights offering, contact Broadridge Corporate Issuer Solutions, Inc. at (855) 793-5068. Broadridge acted as the Subscription and Information Agent for the rights offering on behalf of the Company.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in-vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company's revolutionary BACcel™ platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the BACcel system development pipeline, the Company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays. For more information, visit: www.acceleratediagnostics.com.

Forward-Looking Statements

This press release contains words such as "expects," "shall," "will," "believes" and other similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company's current beliefs, known events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company's results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. For a full discussion of the Company's risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in Item 1A in the Company's Transition Report on Form 10-KT, filed with the SEC on March 20, 2013. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

 


'/>"/>
SOURCE Accelerate Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
2. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
3. ZyDoc Selects Health Fidelitys REVEAL™ Natural Language Processing (NLP) Platform to Accelerate Time to Value for its MediSapien Web Services
4. Berg Pharma and the Parkinsons Institute ink R&D collaboration to drive disease understanding and accelerate therapeutic and diagnostic development in Parkinsons Disease
5. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
6. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
7. Medical Alarm Provides Investor Update -- Company Surpassing Previous Record Order Levels as Consumer Interest Accelerates
8. Medical Devices Market in China to 2018 - Government Reforms Aimed at Strengthening the Healthcare System and Expanding Access will Accelerate Growth
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
11. Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... PUNE, India , April 29, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" market research report ... pipeline, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology company built ... Dr. Alfredo Zurlo as Chief Medical Officer. ... years clinical experience and a proven track record in ... at Mologen AG where he was Chief Medical Officer ... held various positions at F Hoffmann La Roche and ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) ... at Manhattan College, made the cut. The WUGC is being held in London, England this ... the gold in the men’s division, another gold in the women’s masters division, and a ...
(Date:5/2/2016)... ... , ... Pregnancy Awareness Month offers a great time to get familiar with ... are ready to have a baby, it’s best to get started before age becomes ... Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant to ...
(Date:5/2/2016)... ... May 02, 2016 , ... A ... completed two groundbreaking studies that determined that the adjustability and adaptability of pediatric ... the prevention of pressure injuries, which are now referred to as “pressure injuries” ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) ... B Payment Model Could Transform the Pharma Landscape .” CMS recently proposed a test ... spend on provider-administered drugs while preserving care provided to beneficiaries. The webinar will review ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board Company- ... prices announced today the outcome of their partnership with Yoloha Yoga- producers of high ... Yoga Board.” , SUP yoga has seen a dramatic rise in popularity throughout the ...
Breaking Medicine News(10 mins):